Skip to main content

OpenEvidence Benchmark — What the Leader Sources From

Research on OpenEvidence's licensed corpus as a benchmark / reference for what a leading clinical-AI platform draws from. Used as a reality-check on Starlight's own data-source mix — sister pages in this section catalog what's available to us (free / paid / standardized).

About OpenEvidence

OpenEvidence is the most widely used medical AI platform among verified U.S. physicians, founded in 2021 by Daniel Nadler (PhD, Harvard; previously founded Kensho, acquired by S&P Global for $550M) and Zachary Ziegler (CTO). As of early 2026, it has a $12 billion valuation, ~$700M in total funding, ~$150M ARR, and is used by 40%+ of U.S. physicians across 10,000+ hospitals.

Source Data Sets — Complete Enumeration

OpenEvidence draws from a proprietary corpus of 35+ million peer-reviewed medical publications via a combination of licensed content partnerships, open biomedical databases, and clinical guideline agreements.

Licensed Journal & Publisher Partnerships

SourceDescriptionPricing Model
NEJMFull-text content from the world's most-cited medical journal. Partnership Feb 2025.Licensed/Subscription — Institutions ~$175-$4,000+/yr; OpenEvidence pays licensing fee
JAMA Network (12 journals)JAMA and 11 specialty journals. Multi-year agreement June 2025.Licensed/Subscription — Institutional $2,000-$20,000+/yr
Wiley (400+ journals & books)Comprehensive portfolio including Holland-Frei Cancer Medicine, Rook's Dermatology, Yamada's Gastroenterology. Partnership March 2026.Licensed/Subscription — Institutional bundles $10K-$100K+/yr
Cochrane DatabaseGold-standard evidence syntheses + Cochrane Clinical Answers. Licensed via Wiley.Licensed/Subscription — Institutional ~$2,000-$20,000+/yr

Clinical Guideline & Society Partnerships

SourceDescriptionPricing Model
NCCNClinical Practice Guidelines in Oncology — standard of careProprietary License — institutional-level
ACCAmerican College of Cardiology — cardiovascular guidancePartnership/Licensed — member-gated
ADAAmerican Diabetes Association — diabetes management guidelinesPartnership — partly open-access
AAFPAmerican Academy of Family Physicians — evidence-based family medicinePartnership — member/subscriber-based
AAOSAmerican Academy of Orthopaedic Surgeons — orthopaedic guidelinesPartnership — society-gated
AAO-HNSAmerican Academy of Otolaryngology — ENT guidelinesPartnership — society-gated
ACEPAmerican College of Emergency Physicians — emergency medicine policiesPartnership — society-gated

Open/Public Biomedical Databases

SourceDescriptionCost
PubMed / MEDLINE~36 million citations/abstracts from NLM. Backbone of the 35M+ corpus.Free (NIH/NLM)
PubMed Central (PMC)Full-text archive of biomedical literatureFree (NIH)
FDA Drug LabelsDrug prescribing information, indications, interactionsFree (FDA public data)
ClinicalTrials.govRegistry of clinical studiesFree (NIH)
GeneReviewsExpert-authored genetic condition reviewsFree (NIH/NCBI Bookshelf)

Proprietary / Internal Data

SourceDescription
Proprietary medical LLMsVertical language models trained exclusively on licensed medical texts (not open internet)
Clinician feedback dataRLHF from 100M+ clinical consultations
Clinical calculators50+ widely-used calculators (cardiovascular risk, kidney function, etc.)

Pricing Models Summary

CategoryModelCost Range
NEJM, JAMA, Wiley journalsSubscription/Institutional License$199-$100,000+/yr
Cochrane LibrarySubscription/Institutional License$2,000-$20,000+/yr
NCCN GuidelinesProprietary LicenseVaries (institutional)
Medical Society GuidelinesPartnership/Membership-gatedVaries by society
PubMed/MEDLINE, PMCFree / Open Access$0
FDA Drug LabelsFree / Open Access$0
ClinicalTrials.govFree / Open Access$0
GeneReviewsFree / Open Access$0
Key Insight

OpenEvidence's "gold in, gold out" strategy means it pays significant content licensing fees to premium publishers (NEJM, JAMA, Wiley/Cochrane, NCCN) while supplementing with open-access biomedical databases. These licensing costs are a major operating expense and represent a growing data moat.

Enterprise API License Status

Current State: Emerging, Not Yet Broadly Available

AspectStatus
Public API❌ No publicly available developer API or self-service portal
Enterprise Licensing✅ In development. Revenue includes "API licensing for clinical decision support integration"
Microsoft/Dragon Copilot✅ OpenEvidence agent service embedded into Dragon Copilot (Oct 2025)
EHR Integration (Epic/FHIR)🔄 Early FHIR-based pilots with Epic underway
Enterprise PricingProjected $500-$2,000/user/year for health systems; large contracts $500K-$2M/year
Current Revenue ModelPharmaceutical/medical device advertising ($70-$1,000+ CPMs); free for clinicians

Enterprise Roadmap

Current (2026):    Free for physicians → Ad-supported ($124 ARPU)
Near-term: Microsoft Dragon Copilot integration (enterprise agent service)
FHIR-based EHR integration pilots (Epic)
Future: Per-seat enterprise licensing ($500–$2,000/seat/yr)
API access for clinical decision support integration
Health system contracts ($500K–$2M/yr)

Bottom Line

OpenEvidence does not currently offer a standalone enterprise API license for general purchase. However, they are actively building toward enterprise integration through:

  1. The Microsoft Dragon Copilot collaboration (first major enterprise integration)
  2. FHIR-based EHR integration pilots with Epic
  3. Planned API licensing for clinical decision support

For API access, contact OpenEvidence directly at their enterprise team or via media@openevidence.com.

Detailed Subscription Pricing (March 2026 Research)

These are surprisingly affordable for individual/personal use. Deepak and Erik can pick these up directly.

Individual Subscriptions — Reading Access

SourcePlanPriceHow to Subscribe
NEJMOnline only~$189/yrNEJM Store2026 pricing PDF
NEJMPrint + Online~$259/yrSame store
JAMA (main journal)Online only$238/yrJAMA Network Store
JAMA DermatologyIndividual$186/yrJAMA Network Store
JAMA OncologyIndividual$649/yrJAMA Network Store
JAMA Network (all 12)Via AMA Membership~$420/yrAMA Member Benefits — includes ALL JAMA journals
Cochrane LibraryIndividual license$265-$495/yrContact cs-cochrane@wiley.com
Wiley (individual journals)Per-journalVaries by titleCheck each journal on Wiley Online Library
Recommended Immediate Purchases

For Dr. P's clinical reference (~$430/yr total):

  • NEJM Online ($189/yr) — the most-cited medical journal
  • JAMA via AMA Membership ($420/yr) — gets all 12 JAMA journals + AMA benefits

This is a rounding error for the practice and gives Dr. P direct access to the world's best medical literature.

Reading Access vs. Building With — Critical Distinction

Use CaseWhat You NeedCostStatus
Dr. P reads journals for clinical referenceIndividual subscription$189-$495/yr eachBuy now
Embed content in Starlight Practice AI featuresCommercial/API licenseCustom negotiationContact licensing teams
RAG over full-text articles for clinical AIText & Data Mining (TDM) agreementCustom negotiationContact licensing teams
Display article snippets to usersRedistribution licenseCustom negotiationFuture (requires traction)

Free APIs — Build on These Today

These have free programmatic access and can power AI features immediately:

SourceAPIWhat You GetRate Limits
PubMed / MEDLINENCBI E-utilities36M+ citations and abstracts, full search3 req/sec (free), 10 req/sec (with API key)
PubMed Central (PMC)PMC APIFull-text open access articles, bulk downloadFree, generous limits
CochraneCochrane APIReview metadata, structured dataAvailable — data request form
ClinicalTrials.govFree APITrial registry dataFree
FDA Drug LabelsDailyMed APIPrescribing information, interactionsFree
CDC DataVarious APIsImmunization schedules, growth chartsFree
NIH RePORTERRePORTER APIResearch funding and project dataFree
Build Strategy

Phase 1 (Now): Build on PubMed/PMC APIs — free, 36M+ papers. This is what OpenEvidence started with before adding licensed content.

Phase 2 (With traction): Negotiate TDM/API licenses with NEJM and JAMA. NEJM explicitly works with 3rd parties to "enhance healthcare applications with research and evidence."

Phase 3 (Scale): Submit Cochrane data request form for systematic review data. Contact Wiley re: Cochrane API access (Deborah Pentesco-Murphy at Wiley).

Relevance to Starlight Practice

Immediate Opportunities

  • AAP Guidelines Integration: The wellness check schedule (2, 4, 6, 9, 12, 15, 18, 24, 30 months) is already implemented. Future AI could provide clinical guidance at each milestone.
  • Vaccine Schedules: CDC/ACIP immunization schedules are public data that could be integrated.
  • Developmental Screening: M-CHAT and other screening tools mentioned in the patient journey could be AI-enhanced.
  • PubMed-powered clinical Q&A: Build RAG over PubMed abstracts for evidence-based answers at point of care — free, no licensing needed.

Future Integration Points

  • Clinical decision support at point of care (PubMed RAG → licensed full-text RAG)
  • Evidence-based answers to parent questions
  • Developmental milestone tracking with AI assessment
  • Drug interaction checking via FDA drug label API
  • Growth chart percentiles via CDC data

Open-Access Resources for Pediatrics

These free resources are most relevant for building AI features:

ResourceURLUse CaseAPI Available
AAP Bright Futuresbrightfutures.aap.orgWellness visit guidelines and schedulesNo (reference)
CDC Immunization Schedulescdc.gov/vaccines/schedulesVaccine schedule integrationYes (CDC API)
M-CHAT-R/Fmchatscreen.comAutism screening at 18/24 monthsNo (manual)
ASQ-3agesandstages.comDevelopmental screening questionnairesNo (licensed tool)
PubMedpubmed.ncbi.nlm.nih.govMedical literature search + AI RAGYes (E-utilities, free)
PubMed Centralpmc.ncbi.nlm.nih.govFull-text articles for AIYes (PMC API, free)
CDC Growth Chartscdc.gov/growthchartsPediatric growth percentile trackingYes (public data)
FDA DailyMeddailymed.nlm.nih.govDrug labels, interactions, dosingYes (free API)
ClinicalTrials.govclinicaltrials.govActive trials relevant to patientsYes (free API)